Ayala Pharmaceuticals, Inc.
ADXSOTCHealthcare
$0.60
+$0.00(+0.00%)
Market Cap$25707577
P/E Ratio—
52W High$0.801
52W Low$0.0011
Ayala Pharmaceuticals, Inc. (ADXS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADXS · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2023-12 | 2022-10 | 2021-10 | 2020-10 | 2019-10 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($48.07M) | ($14.36M) | ($17.86M) | ($26.47M) | ($17.79M) |
| Depreciation & Amort. | $0.37M | $0.31M | $0.99M | $1.98M | $0.15M |
| Stock-Based Comp. | $1.22M | $2.24M | $2.68M | $1.57M | $0.73M |
| Change in Working Capital | $1.13M | $0.31M | $0.42M | ($1.85M) | $1.97M |
| Net Cash from Operations | ($29.48M) | ($15.28M) | ($15.44M) | ($21.94M) | ($14.95M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | ($0.20M) | ($0.46M) | ($0.75M) | ($1.33M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.23M | $0.00M |
| Net Cash from Investing | $5.95M | ($0.17M) | ($0.01M) | ($0.75M) | ($1.58M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($5.25M) | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | — | — | — | — | — |
| Net Cash from Financing | $26.00M | ($0.96M) | $31.89M | $15.50M | $7.08M |
| Free Cash Flow | |||||
| Free Cash Flow | ($29.48M) | ($15.48M) | ($15.90M) | ($22.69M) | ($16.28M) |
| FCF Margin %(computed) | — | — | -490.71% | — | -697.51% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Ayala Pharmaceuticals, Inc. data
About Ayala Pharmaceuticals, Inc. (ADXS) Cash Flow Statement
Ayala Pharmaceuticals, Inc. generated operating cash flow of ($0.03B) and free cash flow of ($0.03B) for 2023 — a FCF margin of -226807.69%. Capital expenditure was $0.00B.
Frequently asked questions
ADXS · 4 questionsAyala Pharmaceuticals, Inc. generated free cash flow of ($0.03B) for 2023, down 90.4% year-over-year.
ADXS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15